Advertisement

Topics

Takeda Sells Two Drugs for $5.7B+, Licenses a Third, in Deals Aimed at Refocusing Pipeline

10:00 EDT 9 May 2019 | Genetic Engineering News

Takeda Pharmaceutical has agreed to sell two of its non-core drugs in deals that could generate up to $5.7 billion for the pharma giant—and are intended to refocus its portfolio on five key business areas following its recently-completed $59.8 billion purchase of Shire. Takeda said it will sell its dry eye disease treatment Xiidra® (lifitegrast […]

The post Takeda Sells Two Drugs for $5.7B+, Licenses a Third, in Deals Aimed at Refocusing Pipeline appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: Takeda Sells Two Drugs for $5.7B+, Licenses a Third, in Deals Aimed at Refocusing Pipeline

NEXT ARTICLE

More From BioPortfolio on "Takeda Sells Two Drugs for $5.7B+, Licenses a Third, in Deals Aimed at Refocusing Pipeline"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...